Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
BERWYN, Pa.–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders,…
Details